ERBB2 and breast carcinoma: Given that HER2 overexpression is observed in approx. 20% of breast cancer cases and serves as a critical determinant of prognosis and therapeutic response [17], the refinement of 89Zr-based HER2-targeting tracers represents a significant advancement in precision oncology.